It is tempting to speculate that a coordinated expression of PgR and cytoplasmic growth signalling factors including S6K2/4EBP1 may facilitate the proliferative and oncogenic role of PgR, promoting tumour progression and therapy resistance. The gene discussed is RPS6KB2; the disease is neoplasm.